These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 17269897)
1. Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. Ritter JK Expert Opin Drug Metab Toxicol; 2007 Feb; 3(1):93-107. PubMed ID: 17269897 [TBL] [Abstract][Full Text] [Related]
2. Substrate selectivity of human intestinal UDP-glucuronosyltransferases (UGTs): in silico and in vitro insights. Tripathi SP; Bhadauriya A; Patil A; Sangamwar AT Drug Metab Rev; 2013 May; 45(2):231-52. PubMed ID: 23461702 [TBL] [Abstract][Full Text] [Related]
3. Targeted screen for human UDP-glucuronosyltransferases inhibitors and the evaluation of potential drug-drug interactions with zafirlukast. Oda S; Fujiwara R; Kutsuno Y; Fukami T; Itoh T; Yokoi T; Nakajima M Drug Metab Dispos; 2015 Jun; 43(6):812-8. PubMed ID: 25834030 [TBL] [Abstract][Full Text] [Related]
4. Gender-dependent differences in uridine 5'-diphospho-glucuronosyltransferase have implications in metabolism and clearance of xenobiotics. Liu W; Kulkarni K; Hu M Expert Opin Drug Metab Toxicol; 2013 Dec; 9(12):1555-69. PubMed ID: 24011176 [TBL] [Abstract][Full Text] [Related]
5. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Fisher MB; Paine MF; Strelevitz TJ; Wrighton SA Drug Metab Rev; 2001; 33(3-4):273-97. PubMed ID: 11768770 [TBL] [Abstract][Full Text] [Related]
6. Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediators. Knights KM; Miners JO Drug Metab Rev; 2010 Feb; 42(1):63-73. PubMed ID: 19780654 [TBL] [Abstract][Full Text] [Related]
7. N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases. Kaivosaari S; Finel M; Koskinen M Xenobiotica; 2011 Aug; 41(8):652-69. PubMed ID: 21434773 [TBL] [Abstract][Full Text] [Related]
8. Effects of cell differentiation and assay conditions on the UDP-glucuronosyltransferase activity in Caco-2 cells. Zhang H; Tolonen A; Rousu T; Hirvonen J; Finel M Drug Metab Dispos; 2011 Mar; 39(3):456-64. PubMed ID: 21098645 [TBL] [Abstract][Full Text] [Related]
9. First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics. Wu B; Kulkarni K; Basu S; Zhang S; Hu M J Pharm Sci; 2011 Sep; 100(9):3655-81. PubMed ID: 21484808 [TBL] [Abstract][Full Text] [Related]
10. The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Miners JO; Mackenzie PI; Knights KM Drug Metab Rev; 2010 Feb; 42(1):196-208. PubMed ID: 19795925 [TBL] [Abstract][Full Text] [Related]
11. Topological aspects of oligomeric UDP-glucuronosyltransferases in endoplasmic reticulum membranes: advances and open questions. Bock KW; Köhle C Biochem Pharmacol; 2009 May; 77(9):1458-65. PubMed ID: 19150343 [TBL] [Abstract][Full Text] [Related]
12. Use of cloned and expressed human liver UDP-glucuronosyltransferases for analysis of drug glucuronide formation and assessment of drug toxicity. Burchell B; Ebner T; Baird S; Bin Senafi S; Clarke D; Brierley C; Sutherland L Environ Health Perspect; 1994 Nov; 102 Suppl 9(Suppl 9):19-23. PubMed ID: 7698078 [TBL] [Abstract][Full Text] [Related]
13. Drug and xenobiotic glucuronidation catalysed by cloned human liver UDP-Glucuronosyltransferases stably expressed in tissue culture cell lines. Wooster R; Ebner T; Sutherland L; Clarke D; Burchell B Toxicology; 1993 Oct; 82(1-3):119-29. PubMed ID: 8236271 [TBL] [Abstract][Full Text] [Related]
14. Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Mizuma T Int J Pharm; 2009 Aug; 378(1-2):140-1. PubMed ID: 19486934 [TBL] [Abstract][Full Text] [Related]
15. A high throughput assay for the glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin by recombinant human UDP-glucuronosyltransferases and liver microsomes. Rahikainen T; Häkkinen MR; Finel M; Pasanen M; Juvonen RO Xenobiotica; 2013 Oct; 43(10):853-61. PubMed ID: 23551063 [TBL] [Abstract][Full Text] [Related]
16. Wedelolactone metabolism in rats through regioselective glucuronidation catalyzed by uridine diphosphate-glucuronosyltransferases 1As (UGT1As). Li L; Huang XJ; Peng JL; Zheng MY; Zhong DF; Zhang CF; Chen XY Phytomedicine; 2016 Apr; 23(4):340-9. PubMed ID: 27002404 [TBL] [Abstract][Full Text] [Related]
17. Catalytic activities of cytochrome P450 enzymes and UDP-glucuronosyltransferases involved in drug metabolism in rat everted sacs and intestinal microsomes. Takemoto K; Yamazaki H; Tanaka Y; Nakajima M; Yokoi T Xenobiotica; 2003 Jan; 33(1):43-55. PubMed ID: 12519693 [TBL] [Abstract][Full Text] [Related]
18. Multiplexed Targeted Quantitative Proteomics Predicts Hepatic Glucuronidation Potential. Margaillan G; Rouleau M; Klein K; Fallon JK; Caron P; Villeneuve L; Smith PC; Zanger UM; Guillemette C Drug Metab Dispos; 2015 Sep; 43(9):1331-5. PubMed ID: 26076694 [TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications. Guillemette C; Lévesque É; Rouleau M Clin Pharmacol Ther; 2014 Sep; 96(3):324-39. PubMed ID: 24922307 [TBL] [Abstract][Full Text] [Related]
20. Ontogeny of hepatic glucuronidation; methods and results. Krekels EH; Danhof M; Tibboel D; Knibbe CA Curr Drug Metab; 2012 Jul; 13(6):728-43. PubMed ID: 22452455 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]